Blue Edge Capital Has Cut Celgene Corp. (CELG) Holding; 9 Bullish Analysts Covering Bellicum Pharmaceuticals, Inc. (BLCM)

February 19, 2018 - By Vivian Park

Blue Edge Capital Llc decreased Celgene Corp. (CELG) stake by 3.37% reported in 2017Q3 SEC filing. Blue Edge Capital Llc sold 466 shares as Celgene Corp. (CELG)’s stock declined 3.49%. The Blue Edge Capital Llc holds 13,342 shares with $1.95 billion value, down from 13,808 last quarter. Celgene Corp. now has $71.65B valuation. The stock decreased 0.92% or $0.88 during the last trading session, reaching $95.26. About 5.78 million shares traded. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since February 19, 2017 and is uptrending. It has outperformed by 0.30% the S&P500.

Among 11 analysts covering Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), 9 have Buy rating, 1 Sell and 1 Hold. Therefore 82% are positive. Bellicum Pharmaceuticals Inc had 21 analyst reports since July 24, 2015 according to SRatingsIntel. Cantor Fitzgerald initiated Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) on Wednesday, November 2 with “Buy” rating. As per Monday, June 12, the company rating was maintained by Jefferies. Jefferies maintained it with “Buy” rating and $16.0 target in Tuesday, September 12 report. The rating was initiated by Citigroup with “Neutral” on Thursday, February 25. Raymond James maintained the shares of BLCM in report on Wednesday, August 9 with “Outperform” rating. Jefferies maintained the stock with “Buy” rating in Tuesday, August 9 report. The stock of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) earned “Outperform” rating by Raymond James on Thursday, December 1. On Friday, June 3 the stock rating was initiated by SunTrust with “Buy”. The rating was maintained by Citigroup with “Neutral” on Tuesday, August 9. As per Wednesday, August 19, the company rating was downgraded by Zacks. See Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) latest ratings:

16/02/2018 Broker: Citigroup Rating: Buy New Target: $27.0
31/01/2018 Broker: SunTrust Rating: Buy New Target: $18.0
31/01/2018 Broker: Wells Fargo Rating: Hold New Target: $6.0 Downgrade
12/09/2017 Broker: Jefferies Rating: Buy New Target: $16.0 Maintain

The stock increased 10.55% or $0.63 during the last trading session, reaching $6.6. About 1.22M shares traded or 68.78% up from the average. Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has risen 32.63% since February 19, 2017 and is uptrending. It has outperformed by 15.93% the S&P500.

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company has market cap of $219.49 million. The Company’s clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. It currently has negative earnings. The companyÂ’s preclinical product candidates include BPX-601, a GoCAR-T product candidate for treating solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma.

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.17, from 1.34 in 2017Q2. It worsened, as 44 investors sold CELG shares while 457 reduced holdings. 133 funds opened positions while 451 raised stakes. 603.99 million shares or 0.25% more from 602.51 million shares in 2017Q2 were reported. Moreover, Peregrine Asset Advisers has 0.13% invested in Celgene Corporation (NASDAQ:CELG) for 1,664 shares. First Long Island Llc reported 125,189 shares. Robecosam Ag holds 0.01% or 800 shares in its portfolio. Montag & Caldwell Ltd Co holds 743,460 shares. Bremer Natl Association accumulated 25,026 shares. Bancorpsouth holds 0.04% or 2,852 shares. Numeric Ltd Liability Corp holds 0.08% in Celgene Corporation (NASDAQ:CELG) or 67,100 shares. Walter & Keenan Fincl Consulting Mi Adv has invested 0.54% in Celgene Corporation (NASDAQ:CELG). Polaris Greystone Group Limited Liability Corporation accumulated 14,855 shares or 0.19% of the stock. Bahl & Gaynor has invested 0% in Celgene Corporation (NASDAQ:CELG). Natixis has invested 0.22% in Celgene Corporation (NASDAQ:CELG). The New York-based Hilton Capital Mgmt Limited has invested 0.17% in Celgene Corporation (NASDAQ:CELG). Zwj Counsel holds 2.5% or 219,396 shares in its portfolio. Epoch Prtnrs has 96,326 shares. Asset Strategies holds 3,051 shares or 0.25% of its portfolio.

Among 33 analysts covering Celgene Corporation (NASDAQ:CELG), 19 have Buy rating, 2 Sell and 12 Hold. Therefore 58% are positive. Celgene Corporation had 132 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Overweight” rating given on Thursday, October 1 by JP Morgan. As per Thursday, October 5, the company rating was downgraded by Morgan Stanley. The stock has “Buy” rating by Canaccord Genuity on Friday, October 27. Guggenheim maintained the stock with “Buy” rating in Thursday, December 21 report. The stock has “Buy” rating by Suntrust Robinson on Friday, April 29. Cantor Fitzgerald maintained the shares of CELG in report on Tuesday, August 22 with “Buy” rating. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, July 27. The rating was maintained by Barclays Capital with “Equal-Weight” on Friday, October 20. As per Friday, October 27, the company rating was downgraded by JMP Securities. Cantor Fitzgerald maintained the stock with “Buy” rating in Thursday, July 6 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: